N
Navonil De Sarkar
Researcher at Fred Hutchinson Cancer Research Center
Publications - 35
Citations - 2725
Navonil De Sarkar is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 11, co-authored 26 publications receiving 1664 citations. Previous affiliations of Navonil De Sarkar include Indian Statistical Institute & University of Washington.
Papers
More filters
Journal ArticleDOI
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Colin C. Pritchard,Joaquin Mateo,Michael Walsh,Navonil De Sarkar,Wassim Abida,Himisha Beltran,Andrea Garofalo,Roman Gulati,Suzanne Carreira,Rosalind A. Eeles,Olivier Elemento,Mark A. Rubin,Dan R. Robinson,Robert J. Lonigro,Maha Hussain,Arul M. Chinnaiyan,Arul M. Chinnaiyan,Jake Vinson,Julie Filipenko,Levi A. Garraway,Mary-Ellen Taplin,Saud H. AlDubayan,G. Celine Han,Mallory Beightol,Colm Morrissey,Belinda Nghiem,Heather H. Cheng,Bruce Montgomery,Tom Walsh,Silvia Casadei,Silvia Casadei,Michael F. Berger,Liying Zhang,Ahmet Zehir,Joseph Vijai,Howard I. Scher,Charles L. Sawyers,Nikolaus Schultz,Philip W. Kantoff,David B. Solit,Mark E. Robson,Eliezer M. Van Allen,Kenneth Offit,Johann S. de Bono,Peter S. Nelson,Peter S. Nelson +45 more
TL;DR: The frequency of germline mutations in DNA-repair genes among men with metastatic prostate cancer significantly exceeded the prevalence of 4.6% among 499 men with localized prostate cancer and 2.7% in the Exome Aggregation Consortium, which includes 53,105 persons without a known cancer diagnosis.
Journal ArticleDOI
Genomic correlates of clinical outcome in advanced prostate cancer.
Wassim Abida,Joanna Cyrta,Joanna Cyrta,Glenn Heller,Davide Prandi,Joshua Armenia,Ilsa Coleman,Marcin Cieslik,Matteo Benelli,Dan R. Robinson,Eliezer M. Van Allen,Eliezer M. Van Allen,Andrea Sboner,Tarcisio Fedrizzi,Juan Miguel Mosquera,Brian D. Robinson,Navonil De Sarkar,Lakshmi P. Kunju,Scott A. Tomlins,Yi-Mi Wu,Daniel Nava Rodrigues,Massimo Loda,Massimo Loda,Anuradha Gopalan,Victor E. Reuter,Colin C. Pritchard,Joaquin Mateo,Diletta Bianchini,Susana Miranda,Suzanne Carreira,Pasquale Rescigno,Julie Filipenko,Jacob Vinson,Robert B. Montgomery,Himisha Beltran,Himisha Beltran,Elisabeth I. Heath,Howard I. Scher,Philip W. Kantoff,Mary-Ellen Taplin,Nikolaus Schultz,J. De-Bono,Francesca Demichelis,Peter S. Nelson,Mark A. Rubin,Mark A. Rubin,Arul M. Chinnaiyan,Charles L. Sawyers +47 more
TL;DR: This large analysis integrating mCRPC genomics with histology and clinical outcomes identifies RB1 genomic alteration as a potent predictor of poor outcome, and is a community resource for further interrogation of clinical and molecular associations.
Journal ArticleDOI
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
Yi-Mi Wu,Marcin Cieślik,Robert J. Lonigro,Pankaj Vats,Melissa A. Reimers,Xuhong Cao,Yu Ning,Lisha Wang,Lakshmi P. Kunju,Navonil De Sarkar,Elisabeth I. Heath,Jonathan Chou,Felix Y. Feng,Peter S. Nelson,Peter S. Nelson,Johann S. de Bono,Johann S. de Bono,Weiping Zou,Bruce Montgomery,Ajjai Alva,Dan R. Robinson,Arul M. Chinnaiyan +21 more
TL;DR: Using integrative genomic analysis of 360 metastatic castration-resistant prostate cancer samples, a novel subtype of prostate cancer typified by biallelic loss of CDK12 is identified that is mutually exclusive with tumors driven by DNA repair deficiency, ETS fusions, and SPOP mutations.
Journal ArticleDOI
Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress
Michael D. Nyquist,Alexandra Corella,Ilsa Coleman,Navonil De Sarkar,Arja Kaipainen,Gavin Ha,Roman Gulati,Lisa S Ang,Payel Chatterjee,Jared M. Lucas,Colin C. Pritchard,Gail P. Risbridger,John T. Isaacs,Bruce Montgomery,Colm Morrissey,Eva Corey,Peter S. Nelson,Peter S. Nelson +17 more
TL;DR: While tumor cells lacking TP53/RB1 are highly resistant to all single-agent therapeutics tested, the combination of PARP and ATR inhibition is found to produce significant responses, reflecting a clinically exploitable vulnerability resulting from replication stress.
Journal ArticleDOI
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
Sylvan C. Baca,Sylvan C. Baca,David Y. Takeda,Ji-Heui Seo,Justin H. Hwang,Sheng-Yu Ku,Rand Arafeh,Taylor E. Arnoff,Supreet Agarwal,Connor Bell,Edward P. O’Connor,Xintao Qiu,Sarah Abou Alaiwi,Rosario I. Corona,Marcos A. S. Fonseca,Claudia Giambartolomei,Claudia Giambartolomei,Paloma Cejas,Klothilda Lim,Monica He,Anjali V. Sheahan,Amin Nassar,Jacob E. Berchuck,Lisha G. Brown,Holly M. Nguyen,Ilsa Coleman,Arja Kaipainen,Navonil De Sarkar,Peter S. Nelson,Colm Morrissey,Keegan Korthauer,Mark Pomerantz,Leigh Ellis,Leigh Ellis,Bogdan Pasaniuc,Kate Lawrenson,Kathleen Kelly,Amina Zoubeidi,Amina Zoubeidi,William C. Hahn,William C. Hahn,Himisha Beltran,Henry W. Long,Myles Brown,Eva Corey,Matthew L. Freedman,Matthew L. Freedman +46 more
TL;DR: In this paper, the epigenomic basis of resistance to targeted therapy in cancer was investigated by profiling histone modifications in NEPC and PRAD patient-derived xenografts (PDXs) using chromatin immunoprecipitation and sequencing.